Close
Nordic 9Nordic 9

nxt2b - Nexttobe AB (investor - Private Equity)

Sweden nxt2b.com
See something wrong or missing? Let us know
Offices:Stockholm

NXT2B was founded in 2011 by the Swedish entrepreneur Bengt Ågerup, founder of med tech company Q-Med AB.

NXT2B  is a venture capital/private equity firm with focus on growth equity investments in healthcare, medical devices and specialty pharmaceutical companies.

NXT2B also invests in technology and consumer companies. NXT2B started in 2011 and has invested in more than 30 companies . NXT2B supports its portfolio company management teams to build market leading companies.

Average round investment:5.63M USD
Average number per year:1.0
Distribution: 2022 (1)2013 (1)
Portfolio companies: Sweden Navinci DiagnosticsSweden Scint-X
Mostly invests in: Sweden Sweden (2) Manufacturing (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to nxt2b - Nexttobe AB

Name Criteria
Sweden Ulf Landegren
83%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Linc Invest
82%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Beijer Ventures AB
82%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Sweden Harald Mix
81%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
France Advent France Biotechnology
80%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Broadview Ventures
80%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Spain Ekarpen
80%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Belgium Gemma Frisius Fund
80%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Longwall Ventures
80%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Peppermint Venture Partners
80%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top